Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments

Inclusion criteria * Presence of neovascular age-related macular degeneration (AMD) in the study eye * \>50 years of age * Previous intravitreal anti-VEGF treatment with aflibercept (Eylea®) or with aflibercept and ranibizumab (Lucentis®) in the study eye * Minimum of 6 monthly aflibercept injections * Persisting intraretinal or subretinal fluid or both, despite at least 3 consecutive monthly aflibercept injections in the study eye before switching to faricimab Exclusion criteria * Neovascular conditions other than AMD (e.g., choroidal neovascularisation due to other causes) or co-existence of other retinal disease in the study eye * Significant optical media opacities that would result in poor imaging quality on OCT scans in the study eye * Intraocular surgery in the study eye 3 months before or within 1 month after the treatment switch